Company: DHR
Filing Date: 2025-03-26
Form Type: ARS
Source: 0000313616-25-000085
Chunk: 0

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: ARS
Chunk 0
---
2024 Annual Report

Financial Operating Highlights Danaher (dollars in millions except per share data and number of associates) 2024 2023 Sales $ 23,875 $ 23,890 Operating Profit $ 4,863 $ 5,202 Net Earnings from Continuing Operations $ 3,899 $ 4,221 Net Earnings Per Common Share (Diluted) from Continuing Operations $ 5.29 $ 5.65 Operating Cash Flow from Continuing Operations $ 6,688 $ 6,490 Investing Cash Flow from Continuing Operations $ (1,981) $ (7,048) Financing Cash Flow from Continuing Operations $ (8,385) $ 154 Capital Expenditures $ (1,392) $ (1,383) Capital Disposals $ 13 $ 12 Free Cash Flow from Continuing Operations (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 5,309 $ 5,119 Total Assets $ 77,542 $ 84,488 Total Debt* $ 16,005 $ 18,402 Stockholders’ Equity $ 49,550 $ 53,490 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 65,555 $ 71,892 * Long-Term Debt ($15,500 for 2024 and $16,707 for 2023) plus Notes Payable and Current Portion of Long-Term Debt ($505 for 2024 and $1,695 for 2023) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated.

2024 Segment Revenues Life Sciences $7.3B • 67% Recurring • 33% Nonrecurring • 44% North America • 21% Western Europe • 28% High-Growth Markets • 7% Other Developed Markets Mix Geo Biotechnology $6.8B • 85% Recurring • 15% Nonrecurring • 33% North America • 34% Western Europe • 28% High-Growth Markets • 5% Other Developed Markets Mix Geo Diagnostics $9.8B • 89% Recurring • 11% Nonrecurring • 50% North America • 16% Western Europe • 30% High-Growth Markets • 4% Other Developed Markets Mix Geo Danaher

Rainer M. Blair President and Chief Executive Officer “ 2024 marked a significant milestone— Danaher’s 40